Compare Smith & Nephew plc (SNN) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Synopsys, Inc. — how do they compare? Smith & Nephew plc trades at $30.16 (market cap $12.64B), while Synopsys, Inc. trades at $376.05 (market cap $72.47B). The key difference: Synopsys, Inc. is far larger — about 5.7× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNN | SNPS | |
|---|---|---|
Market Cap | $12.64B | $72.47B |
Sector | Health | Technology |
52-Week High | $38.70 | $645.59 |
52-Week Low | $28.73 | $378.46 |
Enterprise Value | $15.41B | $80.82B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Synopsys (SNPS) trades at $378.47, down 1.51% amid a semiconductor sector downturn. The stock shows bearish technical signals but maintains strong fundamentals with consistent earnings beats and a high analyst buy consensus of 82.76%. Recent news highlights the company's strategic pivot to AI design tools and margin expansion following the Ansys integration.
Outlook remains positive long-term due to SNPS's critical role in AI chip design, though near-term risks include sector volatility and execution of high-margin transitions. The consensus price target of $559.50 implies significant upside, but investors should monitor competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
